Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

NCT02302989 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab 0.5mg

Sponsor

Leonard Feiner, MD, PhD

Collaborators

[object Object]